Across TCGA pan-cancer cohorts, ZNF679 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of ZNF679’s most consistent transcriptional readouts.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where ZNF679 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ZNF679 is over-expressed in tumor.
HNSC, KIRP, and LUSC are the cancer types where ZNF679 tumor–normal differential expression is most reproducible.